A US-based KOL provides insights into the treatment paradigm of triple-negative breast cancer with a focus on the sequential use of ADCs in the second line and beyond. The KOL also highlights the importance of PD-L1 testing to inform clinical decision-making with Keytruda and PARP inhibitors, as well as late-phase pipeline therapies and specific clinical trials. 

This interview was conducted on Aug. 1, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.